Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities

Adachi, Yoshitaka; Ukai, Shun; Sagou, Ken; Fukushima, Norishige; Ozeki, Kazutaka; Kohno, Akio

doi:10.1016/j.bbmt.2018.02.013

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13][14][15][16][17][18][19] Therefore, data on the cumulative burden of the HCT-CI score restricted to CBT have been limited. [20][21][22] Previous studies demonstrated that the cumulative burden of the HCT-CI score failed to predict NRM 20,22 or OS 21,22 among CBT recipients. However, those previous studies included a relatively small number of patients who received CBT, which could have resulted in a lower impact of the cumulative burden of the HCT-CI score on NRM and OS in CBT.…”

Section: Discussionmentioning

confidence: 99%

“…The cumulative burden of HCT‐CI has been validated to predict the probability of NRM and OS in cohorts of patients mainly receiving matched related or unrelated donor allogeneic HCT 11–19 . Therefore, data on the cumulative burden of the HCT‐CI score restricted to CBT have been limited 20–22 . Previous studies demonstrated that the cumulative burden of the HCT‐CI score failed to predict NRM 20,22 or OS 21,22 among CBT recipients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy

Konuma,

Harada,

Shinohara

et al. 2024

American J Hematol

View full text Add to dashboard Cite

We retrospectively evaluated the effect of 17 individual comorbidities, defined by the hematopoietic cell transplantation (HCT)‐specific comorbidity index, on non‐relapse mortality (NRM) and overall survival (OS) in 9531 patients aged between 16 and 70 years who underwent their first allogeneic HCT from 8/8 and 7/8 allele‐matched unrelated donors (8/8 and 7/8 MUDs) or single‐unit unrelated cord blood (UCB) between 2011 and 2020 using data from a Japanese registry database. In the multivariate analysis, infection (adjusted hazard ratio [HR], 1.62, 95% confidence interval [CI], 1.33–1.99 for 8/8 and 7/8 MUDs; adjusted HR, 1.33, 95%CI, 1.12–1.58 for UCB) and moderate/severe hepatic comorbidity (adjusted HR, 1.57, 95%CI, 1.04–2.38 for 8/8 and 7/8 MUDs; adjusted HR, 1.53, 95%CI, 1.09–2.15 for UCB) had a significant impact on NRM in both donor groups. Cardiac comorbidity (adjusted HR, 1.40, 95%CI, 1.08–1.80), mild hepatic comorbidity (adjusted HR, 1.22, 95%CI, 1.01–1.48), rheumatologic comorbidity (adjusted HR, 1.67, 95%CI, 1.11–2.51), renal comorbidity (adjusted HR, 2.44, 95%CI, 1.46–4.09), and severe pulmonary comorbidity (adjusted HR, 1.40, 95%CI, 1.11–1.77) were significantly associated with an increased risk of NRM but only in UCB recipients. Renal comorbidity had the strongest impact on poor OS in both donor groups (adjusted HR, 1.73, 95%CI, 1.10–2.72 for 8/8 and 7/8 MUDs; adjusted HR, 2.24, 95%CI, 1.54–3.24 for UCB). Therefore, unrelated donor selection should be taken into consideration along with the presence of specific comorbidities, such as cardiac, rheumatologic, renal, mild hepatic, and severe pulmonary comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy

Konuma,

Harada,

Shinohara

et al. 2024

American J Hematol

View full text Add to dashboard Cite

show abstract

Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia

Metheny

Politikos

Ballen

et al. 2021

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Impact of a prior history of cancer on prognosis after myeloablative single-unit cord blood transplantation

Okabe

Konuma

Oiwa‐Monna

et al. 2020

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

A prior history of cancer was associated with higher non-relapse mortality or overall mortality in patients undergoing allogeneic haematopoietic cell transplantation. Because it is unclear whether the outcomes after cord blood transplantation are influenced by a prior history of cancer, we retrospectively assessed the prevalence and prognostic impact of a prior history of cancer in adult patients undergoing myeloablative single-unit cord blood transplantation in our institute between 2004 and 2020. The univariate analysis showed that a prior history of cancer did not affect the probability of overall survival; the cumulative incidence of relapse; or non-relapse mortality. In the multivariate analysis, prior history of cancer was not associated with overall mortality, relapse or non-relapse mortality. No patients with a prior history of cancer had experienced prior cancer relapse. A prior history of cancer was not associated with non-relapse mortality or overall mortality following single-unit cord blood transplantation.

show abstract

Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities

Cited by 3 publications

References 39 publications

Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia

Impact of a prior history of cancer on prognosis after myeloablative single-unit cord blood transplantation

Contact Info

Product

Resources

About